Finnish Bioindustries long-term director Carmela Kantor-Aaltonen is retiring in August 2023. M.Sc. Alexandra Peth has been appointed as her successor, in a  Managing Director role for Finnish Bioindustries starting on August 1st, 2023.

Alexandra currently works as Senior Advisor of innovation and finance at Chemical Industry Federation of Finland. She will continue working for Chemical Industry Federation of Finland beside her role as Managing Director of Finnish Bioindustries.

JERSEY CITY, N.J. & TURKU, FINLAND – Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) inhibitor in early clinical development for endometriosis, being evaluated for its potential effect on endometriotic lesions. Endometriosis is a common and chronic condition that affects up to 1 in 10 women of reproductive age, causes abdominal pain and is associated with infertility.

The BioFinland Pitching Competition Final took place at Tiedekulma, University of Helsinki on October 1, 2021. It was organised by Finnish Bioindustries and was part of the European Biotech Week.

Watch the video recording of the event (1h 55 min)